Survodutide cut weight by about 8 to 10% in obesity with type 2 diabetes

Design

Phase 3, multinational, randomised, double-blind, placebo-controlled, 76 weeks

Population

752 adults with type 2 diabetes and BMI of 27 or more; mean age 55.7 years, mean BMI 36.5

Primary outcome

Percent change in body weight and weight loss of at least 5% at week 76

Effect

Weight change -8.2% (3.6 mg) and -9.8% (6.0 mg) vs -3.9% placebo; at least 5% loss 57.6%, 64.5% vs 35.1%

SYNCHRONIZE-2 randomised 752 adults with type 2 diabetes and a BMI of 27 or more to weekly subcutaneous survodutide, a glucagon and GLP-1 receptor dual agonist, at 3.6 mg or 6.0 mg, or to placebo. Mean age was 55.7 years and mean BMI 36.5. The two primary endpoints were percent weight change and a weight loss of at least 5% at week 76.

Using the treatment-regimen estimand, which counts everyone regardless of whether they stayed on treatment, weight fell by 8.2% (95% CI 7.2 to 9.2) with 3.6 mg and 9.8% (8.8 to 10.8) with 6.0 mg, against 3.9% (2.9 to 4.9) with placebo. At least 5% loss occurred in 57.6%, 64.5% and 35.1%. HbA1c fell by 0.9 and 0.8 percentage points against 0.2 with placebo from a baseline of 7.4%.

Gastrointestinal events were reported in 72.8%, 77.7% and 38.6%, generally mild to moderate. The drug is investigational and the trial was funded by its manufacturer. The abstract does not report cardiovascular or kidney outcomes, and there is no head-to-head comparison with current GLP-1 drugs.

• Expect gastrointestinal side effects in about three quarters of patients on this class
• Weight loss in the trial was around 4 to 6 points more than placebo at 76 weeks
• The drug is not approved; this does not change current prescribing
• Compare any future approval with existing agents on cardiovascular and kidney evidence, not weight loss alone

Why it matters

It shows what a glucagon-based agent might add to a crowded class, and that tolerability remains the main constraint.

Don't overread it

A weight and HbA1c trial of an unapproved drug says nothing yet about cardiovascular events, kidney disease or long-term safety.

The statistics, in plain English

The treatment-regimen estimand is a conservative, real-world style of analysis because it includes people who stopped the drug. Differences from placebo were statistically significant (P < 0.001) and the intervals are narrow, but the abstract gives no data on harms beyond gastrointestinal events.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.